Clinical Considerations on Anticoagulation Management in Cardiovascular Diseases During Pregnancy
Article first published online: 31 OCT 2013
© 2013 Wiley Periodicals, Inc.
Drug Development Research
Special Issue: Thrombosis Drugs and Diagnostics. Part II
Volume 74, Issue 8, pages 541–552, December 2013
How to Cite
Goland, S., Zilberman, L. and Elkayam, U. (2013), Clinical Considerations on Anticoagulation Management in Cardiovascular Diseases During Pregnancy. Drug Dev. Res., 74: 541–552. doi: 10.1002/ddr.21113
- Issue published online: 13 DEC 2013
- Article first published online: 31 OCT 2013
- cardiovascular diseases
|Clinical Development Phases I-III Regulatory, Quality, Manufacturing|
Pregnancy-associated thrombosis is an important cause of morbidity and mortality during pregnancy. All anticoagulation options are associated with risks and benefits. Thus, although anticoagulation therapy is an important component of the management of thrombotic complications in pregnancy, it is associated with fetal and maternal complications. Therefore, pregnancy poses a serious therapeutic dilemma for both physicians and their patients. This review summarizes the available data on anticoagulation therapy for thromboembolic prophylaxis in pregnant women focusing on cardiovascular disorders, especially on treatment strategy in pregnant women with mechanical heart valves.